Product logins

Find logins to all Clarivate products below.


Pazopanib

VOTRIENT®

About VOTRIENT®

  • Marketed by Novartis Pharmaceuticals Corporation (United States and European Union) and GlaxoSmithKline plc (Japan)
  • Selective multi-targeted receptor tyrosine kinase inhibitor
  • Treatment of advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma

Review and approval status

June 14, 2010

First E.U. approval

October 19, 2009

First U.S. approval

Actual and expected launch:

  • 2023: Patent expiry: United States
  • 2025: SPC expiries: European Union
  • 2027: Patent expiry: Japan

Patents estimated to expire beginning in 2039

API availability